Literature DB >> 21537970

Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.

Noriaki Yamada1, Keisuke Kumada, Satoshi Kishino, Nobuo Mochizuki, Keiko Ohno, Shinji Ogura.   

Abstract

The distribution of micafungin (MCFG) in tissue fluids, such as cerebrospinal fluid (CSF), pleural effusions, ascites, and wound tissue fluids, was examined in seven patients with invasive fungal infections. MCFG (100-300 mg) was administered once daily over a 1-h intravenous infusion. Blood and tissue fluid samples were collected from 1 to 24 h after infusion. Although two patients had similar MCFG concentrations in their plasma, the concentrations in the CSF differed between these two patients. The concentration in the CSF of one patient was much higher than the MIC(90) for Candida albicans, Candida glabrata, and Aspergillus fumigatus, whereas the MCFG concentration in the CSF of the other patient was comparable to the MIC(90). By contrast, MCFG concentrations in pleural effusions, ascites, and wound tissue fluids were above the MIC(90). These results suggest that intravenous MCFG may be effective to treat invasive fungal infections that invade the organs and tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537970     DOI: 10.1007/s10156-011-0240-3

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  15 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.

Authors:  Arthur W Baker; Eileen K Maziarz; Christopher J Arnold; Melissa D Johnson; Adrienne D Workman; John M Reynolds; John R Perfect; Barbara D Alexander
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

3.  Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.

Authors:  R Welte; P Eller; I Lorenz; M Joannidis; R Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Authors:  Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros
Journal:  Mycopathologia       Date:  2017-07-11       Impact factor: 2.574

Review 5.  Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.

Authors:  Carlo Tascini; Maria Grazia Bongiorni; Enrico Tagliaferri; Antonello Di Paolo; Sarah Flammini; Ezio Soldati; Alessandro Leonildi; Andrea Di Cori; Francesco Menichetti
Journal:  Mycopathologia       Date:  2012-10-17       Impact factor: 2.574

6.  Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

Review 7.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

Review 8.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 9.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642

10.  Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients.

Authors:  Gwénolé Prigent; Nawel Aït-Ammar; Eric Levesque; Arnaud Fekkar; Jean-Marc Costa; Sarra El Anbassi; Françoise Foulet; Christophe Duvoux; Jean-Claude Merle; Eric Dannaoui; Françoise Botterel
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.